Study of adebrelimab plus famitinib and chemo before surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (famitinib) with chemotherapy before surgery for esophageal cancer. The goal is to see if this approach can shrink the tumor and improve surgical outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have esophageal squamous cell carcinoma confirmed by biopsy.
- Your cancer must be at a specific stage (cT1b-2N+ or cT3-4a, any N) that has not spread to distant organs.
- You must not have received any prior treatment for this cancer.
- You must be between 18 and 75 years old.
- You must be in good overall health with adequate blood, liver, and kidney function.
- You must be willing to undergo surgery after the study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an investigational drug called retlirafusp alfa to standard chemotherapy, given before surgery, can improve outcomes for patients with esophageal squamous cell carcinoma. The treatment is given before the tumor is removed, and the trial aims to see if it helps shrink the cancer and improve long-term results.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
This trial tests a combination of three medicines (immunotherapy plus two chemotherapy drugs) given before surgery to shrink esophageal cancer. The goal is to make the tumor smaller and easier to remove completely, potentially improving the chance of a cure.
This trial tests a new approach for patients with a specific type of esophageal cancer that can be surgically removed. You would first receive a combination of an immunotherapy drug (adebrelimab) with chemotherapy and radiation, and then instead of immediate surgery, your doctor would monitor you closely to see if surgery is still needed. This may help some patients avoid surgery while keeping the cancer under control.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.